J 2019

High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact

OBERMANNOVÁ, Radka, Dalibor VALÍK, Dirk HASENCLEVER, Lenka ZDRAŽILOVÁ DUBSKÁ, Ulrich HACKER et. al.

Basic information

Original name

High prevalence of severe hypovitaminosis D in patients with advanced gastric cancer treated with first-line chemotherapy with or without anti-EGFR-directed monoclonal antibody (EXPAND trial) showing no prognostic impact

Authors

OBERMANNOVÁ, Radka (203 Czech Republic, belonging to the institution), Dalibor VALÍK (203 Czech Republic, belonging to the institution), Dirk HASENCLEVER (276 Germany), Lenka ZDRAŽILOVÁ DUBSKÁ (203 Czech Republic, belonging to the institution), Ulrich HACKER (276 Germany), Regina DEMLOVÁ (203 Czech Republic, belonging to the institution), Iveta SELINGEROVA and Florian LORDICK (276 Germany, guarantor)

Edition

European Journal of Cancer, Oxford, Elsevier Science Inc. 2019, 0959-8049

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30204 Oncology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 7.275

RIV identification code

RIV/00216224:14110/19:00108529

Organization unit

Faculty of Medicine

DOI

UT WoS

000473270800013

Keywords in English

Vitamin D; 25-OHD plasma levels; Gastric cancer; Chemotherapy cetuximab; Prognosis

Tags

Tags

International impact, Reviewed
Změněno: 27/1/2021 12:23, Mgr. Tereza Miškechová

Abstract

V originále

Purpose: The goal of our analysis was to study pretherapeutic circulating 25-OHD plasma levels in patients with previously untreated advanced gastric cancer treated in the randomised controlled phase III Erbitux (cetuximab) in combination with Xeloda (capecitabine) and cisplatin in advanced esophago-gastric cancer (EXPAND) trial (NCT00678535) and to explore whether low 25-OHD plasma levels are associated with worse prognosis and may compromise the clinical efficacy of cetuximab. Methods: Six hundred thirty patients with available pretherapeutic 25-OHD plasma levels and treated with chemotherapy based on capecitabine and cisplatin, or chemotherapy and cetuximab, were included. The Cox proportional hazard regression model was used to analyse the association between low 25-OHD and survival in both treatment arms. Results: Majority of study patients were found to have severe vitamin D deficiency. No prognostic impact of 25-OHD plasma levels could be found in our patient cohort, and there was no indication of an interference of 25-OHD plasma levels and the efficacy of treatment with the anti-epidermal growth factor receptor monoclonal antibody cetuximab. Conclusions: Although majority of patients with advanced gastric cancer show hypovitaminosis D deficiency, there is no proof for a negative impact on survival or reduced treatment response. A prospective study is needed to investigate the potential benefit of vitamin D supplementation in this patient cohort during first-line chemotherapy. (C) 2019 Elsevier Ltd. All rights reserved.

Links

LM2015090, research and development project
Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)
Investor: Ministry of Education, Youth and Sports of the CR
NV17-29389A, research and development project
Name: Sekvenční FDG-PET a miRNA jako biomarker změny strategie předoperační léčby u lokálně pokročilého karcinomu žaludku a gastroesofageální junkce